752 related articles for article (PubMed ID: 19339067)
1. Structure-based design of molecular cancer therapeutics.
van Montfort RL; Workman P
Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
[TBL] [Abstract][Full Text] [Related]
2. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
3. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
4. Rational approaches to natural-product-based drug design.
Haustedt LO; Mang C; Siems K; Schiewe H
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
[TBL] [Abstract][Full Text] [Related]
5. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.
Verdine GL; Walensky LD
Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406
[TBL] [Abstract][Full Text] [Related]
6. Chemical approaches to the discovery and development of cancer therapies.
Neidle S; Thurston DE
Nat Rev Cancer; 2005 Apr; 5(4):285-96. PubMed ID: 15803155
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based drug design: combining philosophy with technology.
Bartoli S; Fincham CI; Fattori D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
[TBL] [Abstract][Full Text] [Related]
8. Advances in molecular targets and cancer therapeutics.
Westwell AD
Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
[No Abstract] [Full Text] [Related]
9. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
10. Structural biology and drug discovery.
Congreve M; Murray CW; Blundell TL
Drug Discov Today; 2005 Jul; 10(13):895-907. PubMed ID: 15993809
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets and cancer therapeutics.
Westwell AD
Drug Discov Today; 2004 Dec; 9(24):1042-4. PubMed ID: 15582792
[No Abstract] [Full Text] [Related]
12. Affinity-based screening techniques for enhancing lead discovery.
Comess KM; Schurdak ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
[TBL] [Abstract][Full Text] [Related]
13. Chemical genetic approaches to kinase drug discovery.
Gallion SL; Qian D
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026
[TBL] [Abstract][Full Text] [Related]
14. Multidimensional atomic force microscopy for drug discovery: a versatile tool for defining targets, designing therapeutics and monitoring their efficacy.
Lal R; Arnsdorf MF
Life Sci; 2010 Apr; 86(15-16):545-62. PubMed ID: 20359578
[TBL] [Abstract][Full Text] [Related]
15. Fragment-based lead discovery: leads by design.
Carr RA; Congreve M; Murray CW; Rees DC
Drug Discov Today; 2005 Jul; 10(14):987-92. PubMed ID: 16023057
[TBL] [Abstract][Full Text] [Related]
16. Recent trends in library design: 'rational design' revisited.
Schnur DM
Curr Opin Drug Discov Devel; 2008 May; 11(3):375-80. PubMed ID: 18428091
[TBL] [Abstract][Full Text] [Related]
17. Modeling the 3D structure of GPCRs: advances and application to drug discovery.
Becker OM; Shacham S; Marantz Y; Noiman S
Curr Opin Drug Discov Devel; 2003 May; 6(3):353-61. PubMed ID: 12833668
[TBL] [Abstract][Full Text] [Related]
18. High-throughput virtual screening for drug discovery in parallel.
Toledo-Sherman LM; Chen D
Curr Opin Drug Discov Devel; 2002 May; 5(3):414-21. PubMed ID: 12058617
[TBL] [Abstract][Full Text] [Related]
19. Which aspects of HTS are empirically correlated with downstream success?
Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
[TBL] [Abstract][Full Text] [Related]
20. The role of structure in kinase-targeted inhibitor design.
Pratt DJ; Endicott JA; Noble ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
